MedTrace Logo

A Phase 1 Study Assessing Local Cutaneous Effects of SB204

NCT02250430 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2018-11-19

No results posted yet for this study

Summary

In this study, color (erythema) and pH will be measured on 3 consecutive days after application of 2 doses of SB204 to the cheeks of healthy volunteers.

Conditions

  • Acne Vulgaris

Interventions

DRUG

SB204

Applied topically twice a day on days 1, 2 and 3 to left and right cheeks

Sponsors & Collaborators

  • Novan, Inc.

    lead INDUSTRY

Principal Investigators

  • Stuart Lessin, MD · KGL, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02250430 on ClinicalTrials.gov